Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorMATHARAN, Martin
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorMATHIS, Stephane
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorBONABAUD, Sarah
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorCARLA, Louis
hal.structure.identifierUniversité de Bordeaux [UB]
dc.contributor.authorSOULAGES, Antoine
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorLE MASSON, Gwendal
dc.date.accessioned2023-06-23T10:56:41Z
dc.date.available2023-06-23T10:56:41Z
dc.date.issued2020-05-11
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182780
dc.description.abstractEnIntroduction. Amyotrophic lateral sclerosis (ALS), usually fatal in a few years, is a neurodegenerative disorder where the diagnostic delay, although variable according to the studies, remains too long. The main objective of this study was to determine the average time to diagnose ALS and the role of each physician, general practitioner (GP), or specialist (neurologist or not) involved in the management of these patients. The secondary objective was to propose some simple schemes to quickly identify an ALS suspicion with the aim to reduce this delay. Patients and Methods. This retrospective study evaluated the diagnostic delay (and other intermediate delays) of 90 ALS patients registered in the ALS Center of Bordeaux (France) in 2013. The main clinical signs encountered (and their order of appearance) were studied. Results. The average diagnostic delay was 17 months, with a median diagnostic delay of 12 months. The average diagnostic delay was 2.7 months between the first symptoms and the first complaint to GP, followed by an additional 6.5 month delay before the patient's first visit to a neurologist. This period could be shortened, especially if GP performed additional tests quickly (p=0.01), as the time spent consulting various specialists often extends this crucial step. Overall, diagnostic delay accounted for 40% of the total duration of the disease progression. Conclusion. In relation to total survival time, the diagnostic delay of ALS appears to be proportionately very long, sometimes longer than that observed in previous studies (because it also included the total delay to diagnostic or treatment initiation). The rapid execution of useful additional tests by the first medical doctor, often GP (with the help of a neurologist), considerably reduces the diagnostic delay. The central role of GP seems to be crucial in the management of patients with ALS. The main objective is, of course, to initiate appropriate treatment and care as soon as possible. Finally, based on our results, we also provide a short practical diagram to help nonneurologist practitioners to quickly discuss the diagnosis of ALS in case of some specific symptoms ("red flags"). © 2020 Martin Matharan et al.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enAged
dc.subject.enAmyotrophic Lateral Sclerosis
dc.subject.enBreathing Disorder
dc.subject.enDelayed Diagnosis
dc.subject.enDisease Exacerbation
dc.subject.enElectrodiagnosis
dc.subject.enFemale
dc.subject.enGeneral Practitioner
dc.subject.enHuman
dc.subject.enMajor Clinical Study
dc.subject.enMale
dc.subject.enMedian Survival Time
dc.subject.enMedical Examination
dc.subject.enMedical Specialist
dc.subject.enNeurologist
dc.subject.enPhysician
dc.subject.enRetrospective Study
dc.subject.enRheumatologist
dc.subject.enSurvival Time
dc.title.enMinimizing the Diagnostic Delay in Amyotrophic Lateral Sclerosis: The Role of Nonneurologist Practitioners
dc.title.alternativeNeurol Res Inten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1155/2020/1473981en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed32455015en_US
bordeaux.journalNeurology Research Internationalen_US
bordeaux.volume2020en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue1473981en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04139002
hal.version1
hal.date.transferred2023-06-23T10:56:49Z
hal.exporttrue
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology%20Research%20International&rft.date=2020-05-11&rft.volume=2020&rft.issue=1473981&rft.au=MATHARAN,%20Martin&MATHIS,%20Stephane&BONABAUD,%20Sarah&CARLA,%20Louis&SOULAGES,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée